|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ever-increasing diversity of drug-induced pancreatitis显示文摘With over 100000 hospital admissions per annum,acute pancreatitis remains the leading gastrointestinal cause of hospitalization in the United States and has farreaching impact well beyond.It has become increasingly recognized that druginduced pancreatitis(DIP),despite accounting for less than 3%of all cases,represents an important and growing though often inconspicuous cause of acute pancreatitis.Nevertheless,knowledge of DIP is often curtailed by the limited availability of evidence needed to implicate given agents,especially for nonprescription medications.Indeed,the majority of available data is derived from case reports,case series,or case control studies.Furthermore,the mechanism of injury and causality for many of these drugs remain elusive as a definitive correlation is generally not established(<10%of cases).Several classification systems have been proposed,but no single system has been widely adopted,and periodic updates are required in light of ongoing pharmacologic expansion.Moreover,infrequently prescribed medications or those available over-thecounter(including herbal and other alternative remedies)are often overlooked as a potential culprit of acute pancreatitis.Herein,we review the ever-increasing diversity of DIP and the potential mechanisms of injury with the goal of raising awareness regarding the nature and magnitude of this entity.We believe this manuscript will aid in increasing both primary and secondary prevention of DIP,thus ultimately facilitating more expedient diagnosis and a decrease in DIPrelated morbidity. | Simcha Weissman Muhammad Aziz Ryan B Perumpail Tej I Mehta Rutwik Patel James H Tabibian | 2020 | World Journal of Gastroenterology2020，26，22： | 8 |
| 2 | Impact of gut microbiome in the development and treatment of pancreatic cancer:Newer insights显示文摘The gut microbiome plays an important role in the variation of pharmacologic response.This aspect is especially important in the era of precision medicine,where understanding how and to what extent the gut microbiome interacts with drugs and their actions will be key to individualizing therapy.The impact of the composition of the gut microbiome on the efficacy of newer cancer therapies such as immune checkpoint inhibitors and chimeric antigen receptor T-cell treatment has become an active area of research.Pancreatic adenocarcinoma(PAC)has a poor prognosis even in those with potentially resectable disease,and treatment options are very limited.Newer studies have concluded that there is a synergistic effect for immunotherapy in combination with cytotoxic drugs,in the treatment of PAC.A variety of commensal microbiota can affect the efficacy of conventional chemotherapy and immunotherapy by modulating the tumor microenvironment in the treatment of PAC.This review will provide newer insights on the impact that alterations made in the gut microbial system have in the development and treatment of PAC. | Ayrton I Bangolo Chinmay Trivedi Ishan Jani Silvanna Pender Hirra Khalid Budoor Alqinai Alina Intisar Karamvir Randhawa Joseph Moore Nicoleta De Deugd Shaji Faisal SuchithBoodgere Suresh Parva Gopani Vignesh K Nagesh Tracy Proverbs-Singh Simcha Weissman | 2023 | World Journal of Gastroenterology2023，29，25： | 2 |
| 3 | The cyclin D1 gene is a target of the beta- catenin/LEF-1 pathway显示文摘 | Shtutman M Zhurinsky J Simcha I | 1999 | Proc Natl Acad Scl U S A1999，96，10： | 1 |
| 4 | The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway 显示文摘 | Shtutman M Zhurinsky J Simcha I | 1999 | Proc Natl Acad Sci U S A1999，96，10： | 1 |
| 5 | Familial Ebstein's anomaly显示文摘 | Rosenmann A Arad I Simcha A Schaap T | 1976 | J Med Genet1976，13，： | 1 |
| 6 | The cyclin D1 geneisa target of theβ-catenin/LEF-1 pathway 显示文摘 | Shtutman M Zhurinsky J Simcha I | 1999 | PNAS1999，96，10： | 1 |
| 7 | The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway显示文摘 | Shtutman M Zhurinsky J Simcha I | 1999 | Proc Natl Acad Sci U S A1999，96，： | 1 |
| 8 | The cyclin D1 gene is a target of the β-catenin/ LEF-1 pathway 显示文摘 | SHTUTMAN M ZHURINSKY J SIMCHA I | 1999 | Proc NatlAcad SciUSA1999，96，10： | 1 |
| 9 | The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway显示文摘 | Shtutman M J Zhurinsky I Simcha | 1999 | Proc Natl Acad Sci U S A1999，96，10： | 1 |
| 10 | The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway 显示文摘 | Shtutman M Zhurinsky J Simcha I | 1999 | Proc Natl Acad Sci U S A1999，96，10： | 1 |
| 11 | The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway显示文摘 | Shtutman M Zhurinsky I Simcha I | 1999 | Proc Natl Acad Sci1999，96，10： | 1 |
| 12 | The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway显示文摘 | Shtutman M Zhurinsky J Simcha I | 1999 | Proc Natl Acad Sci U S A1999，96，10： | 1 |
| 13 | Differential nuclear translocation and transactivation potential of beta - catenin and plakoglobin显示文摘 | Simcha I Shtutman M Salomon D | 1998 | J Cell Biol1998，141，6： | 1 |
| 14 | The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway 显示文摘 | Shtutman M Zhurinsky J Simcha I | 1999 | Proc Natl Acad Sci USA1999，96，10： | 1 |
| 15 | Inhibition of β-catenin-mediated transactivation by cadherin derivatives显示文摘 | Sadot E Simcha I Shtutman M | 1998 | Proc Natl Acad Sci USA1998，95，15： | 1 |
| 16 | The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway显示文摘 | Shtutman M Zhurinsky J Simcha I | 1999 | Proc Natl Acad Sci USA1999，96，10： | 1 |
| 17 | Cadherin sequences that inhibit β-catenin signaling:a study in yeast and mammalian cells显示文摘 | Simcha I Kirkpatrick C Sadot E | 2001 | Mol Biol Cell2001，12，8： | 1 |
| 18 | The cyclin D1 is the target gene of the β-catenin/LEF-1 pathway显示文摘 | Shtutman M Zhurinsky J Simcha I | 1999 | Proc Natl Acad Sci USA1999，96，： | 1 |
| 19 | The cyclin D1gene is a target of the beta-catenin/LEF-1 pathway显示文摘 | Shtutman M Zhurinsky J Simcha I | 1999 | Proc Natl Acad Sci U S A1999，96，10： | 1 |
| 20 | Excess beta-catenin promotes accumulation of transcriptionally active p53显示文摘 | Damalas A Ben-Ze'ev A Simcha I | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员